MCID: DGN002
MIFTS: 37

Degenerative Myopia

Categories: Eye diseases

Aliases & Classifications for Degenerative Myopia

MalaCards integrated aliases for Degenerative Myopia:

Name: Degenerative Myopia 12 15
Myopia, Degenerative 45 74
Pathological Myopia 12 17
Degenerative Progressive High Myopia 12
Progressive High Myopia 12
Progressive High Myopia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11829
ICD9CM 36 360.21
MeSH 45 D047728
SNOMED-CT 69 32022003
ICD10 34 H44.2
UMLS 74 C0154778

Summaries for Degenerative Myopia

MalaCards based summary : Degenerative Myopia, also known as myopia, degenerative, is related to myopia and stickler syndrome, type i, nonsyndromic ocular. An important gene associated with Degenerative Myopia is ZNF644 (Zinc Finger Protein 644), and among its related pathways/superpathways are ECM-receptor interaction and ECM proteoglycans. The drugs Ranibizumab and Iodine have been mentioned in the context of this disorder. Affiliated tissues include eye and endothelial, and related phenotypes are behavior/neurological and vision/eye

Related Diseases for Degenerative Myopia

Graphical network of the top 20 diseases related to Degenerative Myopia:



Diseases related to Degenerative Myopia

Symptoms & Phenotypes for Degenerative Myopia

MGI Mouse Phenotypes related to Degenerative Myopia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.43 CHRNG GJD2 LAMA1 LUM NRN1 VEGFA
2 vision/eye MP:0005391 8.92 GJD2 LAMA1 LUM VEGFA

Drugs & Therapeutics for Degenerative Myopia

Drugs for Degenerative Myopia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
2
Iodine Approved, Investigational Phase 4 7553-56-2 807
3
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
4
Povidone Approved Phase 4 9003-39-8
5
Povidone-iodine Approved Phase 4 25655-41-8
6
Ofloxacin Approved Phase 4 82419-36-1 4583
7
Lactitol Investigational Phase 4 585-88-6, 585-86-4 493591
8 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
9 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Ophthalmic Solutions Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
11 cadexomer iodine Phase 4
12
Verteporfin Approved, Investigational Phase 3,Phase 1 129497-78-5
13
Atropine Approved, Vet_approved Phase 2, Phase 3,Early Phase 1,Not Applicable 5908-99-6, 51-55-8 174174
14 Dermatologic Agents Phase 3,Phase 1
15 Pharmaceutical Solutions Phase 3,Phase 2,Early Phase 1,Not Applicable
16 Photosensitizing Agents Phase 3,Phase 1
17 Anti-Asthmatic Agents Phase 2, Phase 3,Early Phase 1,Not Applicable
18 Muscarinic Antagonists Phase 2, Phase 3,Early Phase 1,Not Applicable
19 Bronchodilator Agents Phase 2, Phase 3,Early Phase 1,Not Applicable
20 Respiratory System Agents Phase 2, Phase 3,Early Phase 1,Not Applicable
21 Anti-Arrhythmia Agents Phase 2, Phase 3,Early Phase 1,Not Applicable
22 Autonomic Agents Phase 2, Phase 3,Early Phase 1,Not Applicable
23 Cholinergic Antagonists Phase 2, Phase 3,Early Phase 1,Not Applicable
24 Anesthetics Phase 2, Phase 3,Early Phase 1,Not Applicable
25 Adjuvants, Anesthesia Phase 2, Phase 3,Early Phase 1,Not Applicable
26 Cholinergic Agents Phase 2, Phase 3,Early Phase 1,Not Applicable
27 Mydriatics Phase 2, Phase 3,Early Phase 1,Not Applicable
28 Neurotransmitter Agents Phase 2, Phase 3,Early Phase 1,Not Applicable
29 Peripheral Nervous System Agents Phase 2, Phase 3,Early Phase 1,Not Applicable
30 Parasympatholytics Phase 2, Phase 3,Early Phase 1,Not Applicable
31 Combretastatin Investigational Phase 2 82855-09-2
32
Fosbretabulin Investigational Phase 2 222030-63-9 5351387
33 Antimitotic Agents Phase 2
34 Antineoplastic Agents, Phytogenic Phase 2
35
Bevacizumab Approved, Investigational Phase 1,Not Applicable 216974-75-3
36 Antineoplastic Agents, Immunological Phase 1
37
Triamcinolone Approved, Vet_approved Not Applicable 124-94-7 31307
38
Ketorolac Approved Not Applicable 74103-06-3, 66635-83-4 3826
39 triamcinolone acetonide Not Applicable
40 glucocorticoids Not Applicable
41 Hormones, Hormone Substitutes, and Hormone Antagonists Not Applicable
42 Triamcinolone hexacetonide Not Applicable
43 Hormones Not Applicable
44 Immunologic Factors Not Applicable
45 Immunosuppressive Agents Not Applicable
46 Triamcinolone diacetate Not Applicable
47 Hormone Antagonists Not Applicable
48 Anti-Inflammatory Agents Not Applicable
49 Cyclooxygenase Inhibitors Not Applicable
50 Analgesics Not Applicable

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization Completed NCT03042871 Phase 4 0.5mg intravitreal ranibizumab
2 A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV Unknown status NCT01809223 Phase 3 conbercept, Fixed;conbercept, PRN
3 Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Completed NCT01217944 Phase 3 Ranibizumab;Verteporfin PDT;Sham Ranibizumab;Sham verteporfin PDT
4 A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. Completed NCT02034006 Phase 3 Ranibizumab
5 VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) Completed NCT01249664 Phase 3
6 Low-dose AtropIne for Myopia Control in Children Not yet recruiting NCT03865160 Phase 2, Phase 3 Atropine eye drops, 0.01%;Placebo (NaCl 0.9%) eye drops
7 Effectiveness of Orthokeratology in Decreasing Myopic Progression in a Young Adult Population Enrolled in a Professional Optometric Curriculum Unknown status NCT02623543 Phase 2
8 Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen Completed NCT01037348 Phase 2 ranibizumab 0.5mg
9 Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Completed NCT00470977 Phase 1, Phase 2 ranibizumab injection (0.5 mg)
10 Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia Completed NCT01423149 Phase 2 Combretastatin A-4 Phosphate
11 Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD) Completed NCT00407719 Phase 1 Bevacizumab
12 The Efficacy and Safety of Periocular Acupoint Stimulation on Myopia Progression in Children Completed NCT02064660 Phase 1
13 Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia Completed NCT01968486 Phase 1 PDT standard fluence, ranibizumab;PDT reduced fluence, ranibizumab;ranibizumab
14 Genomewide Screening of Pathological Myopia Unknown status NCT00155753
15 Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases Unknown status NCT03128463 Intravitreal injection of conbercept
16 The Role of SNP of ECM and MMP on the Development of Pathological High Myopia Unknown status NCT00172952
17 The Relationship Between Structure and Visual Function in Myopia Foveoschisis Unknown status NCT02915133
18 Early Vitrectomy for Macular Tractional Maculopathy Unknown status NCT01121978 Not Applicable
19 Efficacy Study of Different Lens Treatments on Chinese Adolescent Myopia Unknown status NCT02001415 Not Applicable
20 Ocular Discomfort Assessment After Intravitreal Injections Completed NCT02806830 Not Applicable Optive
21 Effectiveness of Orthokeratology in Myopia Control Recruiting NCT03465748 Not Applicable
22 Choroidal Response to Novel Spectacle Lens to Control Myopia Progression Recruiting NCT03818880 Not Applicable
23 Atropine 0.01% Eye Drops in Myopia Study Recruiting NCT03508817 Early Phase 1 Atropine Sulfate 0.01% Eye Drops
24 Eye Drops Study for Myopia Control in Schoolchildren Recruiting NCT03402100 Not Applicable eye drops
25 Shanghai Child and Adolescent Large-scale Eye Study -High Myopia Registration Enrolling by invitation NCT03666052
26 Myopia Progression With a Novel Extended Depth of Focus Contact Lens Enrolling by invitation NCT03358862
27 Can Distance Center and Near Center Multifocal Contact Lenses Control Myopia Progression in Children? Not yet recruiting NCT03519490 Not Applicable

Search NIH Clinical Center for Degenerative Myopia

Cochrane evidence based reviews: myopia, degenerative

Genetic Tests for Degenerative Myopia

Anatomical Context for Degenerative Myopia

MalaCards organs/tissues related to Degenerative Myopia:

42
Eye, Endothelial

Publications for Degenerative Myopia

Articles related to Degenerative Myopia:

(show top 50) (show all 91)
# Title Authors Year
1
Prevalence and Associations of Posterior Segment Manifestations in a Cohort of Egyptian Patients with Pathological Myopia. ( 30964360 )
2019
2
Visual Acuity in Pathological Myopia Is Correlated With the Photoreceptor Myoid and Ellipsoid Zone Thickness and Affected by Choroid Thickness. ( 31013344 )
2019
3
Establishment of an induced pluripotent stem cell line (FDEENTi001-A) from a patient with pathological myopia. ( 30611020 )
2019
4
Lamellar macular holes in the eyes with pathological myopia. ( 29725825 )
2018
5
Effects of posterior scleral reinforcement in pathological myopia: a 3-year follow-up study. ( 30554267 )
2018
6
The management of macular hole retinal detachment and macular retinoschisis in pathological myopia; a UK collaborative study. ( 30013156 )
2018
7
Design and Baseline Characteristics of the HELP Study: An Extended and Long-Term Observation of Pathological Myopia in Caucasians. ( 29909408 )
2018
8
Features of optical coherence tomography predictive of choroidal neovascularisation treatment response in pathological myopia in association with fluorescein angiography. ( 28600301 )
2018
9
Inverse hypopyon (hyperoleon) at the posterior segment in pathological myopia. ( 29183904 )
2017
10
6-Year Results of CNV Secondary to Pathological Myopia Treated with Ranibizumab. ( 28192841 )
2017
11
Vascular flow density in pathological myopia: an optical coherence tomography angiography study. ( 28159853 )
2017
12
Comparison of the efficacy of intravitreal ranibizumab for choroidal neovascularization due to pathological myopia with and without a dome-shaped macula. ( 29390361 )
2017
13
Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. ( 27977064 )
2016
14
Optical Coherence Tomography Angiography Of Pathological Myopia Sourced and Idiopathic Choroidal Neovascularization With Follow-Up. ( 27057880 )
2016
15
Effect of a Single Nucleotide Polymorphism in the LAMA1 Promoter Region on Transcriptional Activity: Implication for Pathological Myopia. ( 26862816 )
2016
16
Clinical characteristics and visual outcome of macular hemorrhage in pathological myopia with or without choroidal neovascularization. ( 29018729 )
2016
17
Posterior scleral reinforcement for the treatment of pathological myopia. ( 27162733 )
2016
18
Evaluating the association between pathological myopia and SNPs in RASGRF1. ACTC1 and GJD2 genes at chromosome 15q14 and 15q25 in a Chinese population. ( 23834555 )
2015
19
Effect of pathological myopia on biomechanical properties: a study by ocular response analyzer. ( 25938057 )
2015
20
Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab. ( 25902117 )
2015
21
Optical coherence tomography and pathological myopia: an update of the literature. ( 26265324 )
2015
22
Therapeutic effect of intravitreal injections of ranibizumab for the treatment of macular choroidal neovascularization caused by pathological myopia. ( 26622450 )
2015
23
Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia. ( 25283631 )
2014
24
Comparison of spectral domain and swept-source optical coherence tomography in pathological myopia. ( 24434661 )
2014
25
[Analysis of COL9A2 gene mutations in a Chinese Han population with pathological myopia]. ( 24711017 )
2014
26
Peripapillary intrachoroidal cavitation in pathological myopia. ( 24269422 )
2014
27
Management of Choroidal Neovascularization Secondary to Pathological Myopia: The Era of Changes. ( 26107492 )
2014
28
Intravitreal ranibizumab for the treatment of pathological myopia associated with choroidal neovascularization in Chinese patients. ( 25131225 )
2014
29
Degenerative myopia: myopic macular schisis and the posterior pole buckle. ( 23190923 )
2013
30
Automatic diagnosis of pathological myopia from heterogeneous biomedical data. ( 23799040 )
2013
31
In vivo visualization of perforating vessels and focal scleral ectasia in pathological myopia. ( 24194186 )
2013
32
C-reactive protein and complement components in patients with pathological myopia. ( 23538433 )
2013
33
Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. ( 23449508 )
2013
34
Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome. ( 24026146 )
2013
35
Management of macular hole retinal detachment and macular retinoschisis secondary to pathological myopia: a national survey of UK practice patterns. ( 23949490 )
2013
36
Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection. ( 23007232 )
2012
37
Recent trends in the management of maculopathy secondary to pathological myopia. ( 22159713 )
2012
38
Choroidal neovascularization in pathological myopia. ( 22569156 )
2012
39
Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia. ( 22661650 )
2012
40
Polymorphisms in the CTNND2 gene and 11q24.1 genomic region are associated with pathological myopia in a Chinese population. ( 22759899 )
2012
41
Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia. ( 21586852 )
2011
42
Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia. ( 20881442 )
2011
43
Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series. ( 21775926 )
2011
44
Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month follow-up. ( 21720153 )
2011
45
Pathology of macular foveoschisis associated with degenerative myopia. ( 20814547 )
2010
46
Choroidal filling delay in choroidal neovascularisation due to pathological myopia. ( 19846414 )
2010
47
Low-fluence-rate photodynamic therapy to treat subfoveal choroidal neovascularization in pathological myopia. A study of efficacy and safety. ( 19916015 )
2010
48
Biomechanical considerations: evaluating scleral reinforcement materials for pathological myopia. ( 20436547 )
2010
49
Aqueous humor level of sCD44 in patients with degenerative myopia and primary open-angle glaucoma. ( 19895708 )
2009
50
A genome-wide association analysis identified a novel susceptible locus for pathological myopia at 11q24.1. ( 19779542 )
2009

Variations for Degenerative Myopia

Expression for Degenerative Myopia

Search GEO for disease gene expression data for Degenerative Myopia.

Pathways for Degenerative Myopia

Pathways related to Degenerative Myopia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.44 LAMA1 LUM
2 10.91 LAMA1 LUM
3 10.65 LAMA1 VEGFA
4 10.04 LAMA1 VEGFA

GO Terms for Degenerative Myopia

Cellular components related to Degenerative Myopia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.26 LAMA1 LUM NRN1 VEGFA
2 extracellular matrix GO:0031012 8.8 LAMA1 LUM VEGFA

Molecular functions related to Degenerative Myopia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix structural constituent GO:0005201 8.62 LAMA1 LUM

Sources for Degenerative Myopia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....